Skip to main content

Table 2 Clinicopathological parameters of the enrolled patients and their correlation with GLS1 expression level

From: Kidney-type glutaminase is a biomarker for the diagnosis and prognosis of hepatocellular carcinoma: a prospective study

characteristics

GLS1

p*

p’

r

 

+

++

+++

Age (years)

59.8 ± 10.6

58.7 ± 10.3

58.6 ± 10.4

55.8 ± 10.7

0.002

0.002

-0.071

Gender

0.746

0.280

0.03

 Male

244 (84.1)

396 (82.8)

173 (80.8)

128

(81.0)

 Female

46 (15.9)

82 (17.2)

41 (19.2)

30 (19.0)

Dimension (cm)

4.1 (2.8–6.5)

3.8 (2.3–6.5)

4.5

(2.6-8.0)

4.2 (2.5-7.0)

0.037

0.729

0.008

GPC3

< 0.001

< 0.001

0.202

 

88 (30.5)

101(21.1)

26 (12.2)

24 (15.3)

 +

113 (39.1)

199 (41.6)

68 (31.9)

42 (26.8)

 ++

50 (17.3)

93 (19.5)

59 (27.7)

27 (17.2)

 +++

38 (13.1)

85 (18.8)

60 (28.2)

64 (40.7)

AFP

< 0.001

< 0.001

0.144

 

239 (82.7)

313 (65.5)

136 (63.9)

97 (61.8)

 +

30 (10.3)

105 (22.0)

45 (21.1)

25 (16.0)

 ++

10 (3.5)

36 (7.5)

18 (8.5)

17 (10.8)

 +++

10 (3.5)

24 (5.0)

14 (6.5)

18 (11.4)

MVI

< 0.001

< 0.001

0.112

 Negative

204 (76.4)

307 (70.4)

120 (63.2)

82 (60.7)

 Positive

63 (23.6)

129 (29.6)

70 (36.8)

53 (39.3)

Edmondson-Steiner grade

< 0.001

< 0.001

0.195

 I

30 (11.2)

25 (5.7)

8 (4.2)

3 (2.2)

 II

151 (56.6)

219 (50.2)

83 (43.7)

46 (34.1)

 III

79 (29.6)

185 (42.4)

87 (45.8)

73 (54.1)

 IV

7 (2.6)

7 (1.6)

12 (6.3)

13 (9.6)

TNM stage

0.010

0.017

0.066

 I

151 (56.5)

249 (57.1)

90 (47.4)

61 (45.2)

 II

67 (25.1)

136 (31.2)

62 (32.6)

48 (35.6)

 III-IV

49 (18.4)

51 (11.7)

38 (20.0)

26 (19.2)

T stage

0.019

0.018

0.067

 1

152 (56.9)

250 (57.3)

92 (48.4)

62 (45.9)

 2

67 (25.1)

137 (31.4)

63 (33.2)

48 (35.6)

 3

30 (11.2)

26 (6.0)

20 (10.5)

12 (8.9)

 4

18 (6.7)

23 (5.3)

15 (7.9)

13 (9.6)

F

0.374

0.245

-0.033

 0

180 (67.5)

321 (73.7)

140 (73.7)

98 (72.6)

 1

70 (26.2)

90 (20.6)

36 (18.9)

25 (18.5)

 2

14 (5.2)

20 (4.6)

12 (6.3)

9 (6.7)

 3–4

3 (1.1)

5 (1.1)

2 (1.1)

3 (2.2)

G

0.089

0.399

-0.023

 0

7 (2.6)

11 (2.5)

2 (1.1)

1 (0.7)

 1

88 (33.0)

141 (32.3)

56 (29.5)

54 (40.0)

 2

107 (40.1)

211 (48.4)

90 (47.4)

63 (46.7)

 3–4

65 (24.3)

73 (16.7)

42 (22.1)

17 (12.6)

S

0.551

0.873

0.004

 0

31 (11.6)

44 (10.1)

12 (6.3)

9 (6.7)

 1

38 (14.2)

80 (18.4)

26 (13.7)

20 (14.8)

 2

29 (10.9)

58 (13.3)

35 (18.4)

29 (21.5)

 3

45 (16.9)

69 (15.8)

31 (16.3)

19 (14.0)

 4

124 (46.4)

185 (42.4)

86 (45.3)

58 (43.0)

Ki67

< 0.001

< 0.001

0.170

 

32 (12.0)

32 (7.3)

14 (7.3)

6 (4.4)

 +

105 (39.3)

138 (31.7)

48 (25.3)

29 (21.5)

 ++

116 (43.4)

229 (52.5)

103 (54.2)

72 (53.3)

 +++

14 (5.4)

37 (8.5)

25 (13.2)

28 (20.8)

VEGFR2

0.003

< 0.001

0.099

 

102 (43.0)

161 (39.7)

58 (33.1)

36 (27.5)

 +

93 (39.2)

157 (38.7)

77 (44.0)

54 (41.2)

 ++

31 (13.0)

64 (16.7)

29 (16.6)

29 (22.1)

 +++

11 (4.6)

24 (5.9)

11 (6.7)

12 (9.2)

  1. The p’ was the value of Kendall’s test. The p* was the value of the Kruskal-Wallis test, Chi-square tests and one-way analysis of variance. Dimension are presented as median (interquartile range, IQR). Age is presented as mean ± SD (standard deviation), while categorical variables are presented as patients (%)
  2. Abbreviations: GPC3, glypican3; GLS1: Kidney-type glutaminase; AFP: alpha-fetoprotein; Ki67, antigen identified by a monoclonal antibody; MVI, microvascular invasion, F, the degree of steatosis in the background liver; G, the degree of inflammation in the background liver; S, degree of fibrosis in the background liver; VEGFR2, vascular endothelial growth factor receptor-2; Ki67, antigen identified by monoclonal antibody Ki-67
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us